drugset

drugset / Trial / NCT06712823

An Extension Study to Evaluate Safety and Efficacy of Atumelnant in Participants With Congenital Adrenal Hyperplasia

NCT06712823 ↗

Phase 2 Recruiting 200 enrolled Crinetics Pharmaceuticals Inc.

NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the long-term safety, tolerability, and efficacy of atumelnant (CRN04894).

Timeline

Start: 2025-02-25
Primary completion: 2029-07
Completion: 2029-08

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Atumelnant	Small molecule	—	Oral

Indications